F
39
-8
CI
45
-5
SEE
46
-3
MSFT
46
-11
URBN
44
-2
MTCH
31
-6
HPQ
49
-3
ITW
59
-3
KHC
24
-3
FMC
53
-5
AIG
36
-11
ADP
61
-4
ETN
67
-6
FITB
56
-2
FLS
63
-5
REGN
36
-6
DLTR
24
2
GPC
25
-2
AAPL
39
-4
NFLX
68
2
F
39
-8
CI
45
-5
SEE
46
-3
MSFT
46
-11
URBN
44
-2
MTCH
31
-6
HPQ
49
-3
ITW
59
-3
KHC
24
-3
FMC
53
-5
AIG
36
-11
ADP
61
-4
ETN
67
-6
FITB
56
-2
FLS
63
-5
REGN
36
-6
DLTR
24
2
GPC
25
-2
AAPL
39
-4
NFLX
68
2
Financhill
Back

Intra-Cellular Therapies 10K Form

Buy
54

ITCI
Intra-Cellular Therapies

Last Price:
85.35
Seasonality Move:
25.32%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ITCI News And Ratings

See the #1 stock for the next 7 days that we like better than ITCI

ITCI Financial Statistics

Sales & Book Value

Annual Sales: $462.18M
Cash Flow: $-27.22M
Price / Cash Flow: 0
Annual Sales: $10.80
Price / Book: 7.85

Profitability

EPS (TTM): -0.87000
Net Income (TTM): $-86.37M
Gross Margin: $428.43M
Return on Equity: -10.58%
Return on Assets: -8.93%

Intra-Cellular Therapies Earnings Forecast

Key Intra-Cellular Therapies Financial Ratios

  • The Gross Profit Margin over the past 10 years for ITCI is 92.70%.
  • The Selling, General & Administrative Expenses for ITCI have been equal to 88.68% of Gross Profit Margin.
  • The Research & Development expenses have been 38.98% of Revenue.
  • The Interest Expense is 0.00% of Operating Income.
  • Per Share Earnings over the last 12 years have been positive in 6 years.

Intra-Cellular Therapies Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: ITCI
CUSIP: 46116X
Website: intracellulartherapies.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 7.66
Quick Ratio: 6.94

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 228.59

ITCI Technical Analysis vs Fundamental Analysis

Buy
54
Intra-Cellular Therapies (ITCI) is a Buy

Is Intra-Cellular Therapies a Buy or a Sell?